Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.73 |
| ▸ | JAK2 | O60674 | 2/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.52 |
| ▸ | IDH1 | O75874 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023205 | 0.92 | LCK (0.84) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7017908 | 0.92 | LCK (0.79) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7102850 | 0.88 | LCK (0.69) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7102853 | 0.88 | LCK (0.69) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7022090 | 0.87 | LCK (0.83) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7021297 | 0.86 | LCK (0.79) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7020879 | 0.86 | LCK (0.90) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7020628 | 0.85 | LCK (0.75) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7016983 | 0.85 | LCK (0.87) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7020372 | 0.85 | LCK (0.80) | LCKJAK2JAK3MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |